Filed with the SEC on · accession 0001214659-26-014504
ALZN filed a 8-K (current report) with the SEC on Nov 17, 2026. The FDA declined to support Alzamend Neuro's proposed modification of its Phase II bipolar disorder trial eligibility criteria, stating the trials were not designed as adequate and well-controlled studies. The stock moved -4.2% by the first close after the filing.
The FDA declined to support Alzamend Neuro's proposed modification of its Phase II bipolar disorder trial eligibility criteria, stating the trials were not designed as adequate and well-controlled studies. The company paused the trial, and Massachusetts General Hospital subsequently terminated the related statement of work, though the company plans to request a Type B meeting to discuss moving directly to a Phase III trial.
Close before
$1.18
Nov 16, 2026
First close after
-4.24%
$1.13
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ALZN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ALZN?
Click hereALZN filed a 8-K (Fda rejection). The FDA declined to support Alzamend Neuro's proposed modification of its Phase II bipolar disorder trial eligibility criteria, stating the trials were not designed as adequate and well-controlled studies. The company paused the trial, and Massachusetts General Hospital subsequently terminated the related statement of work, though the company plans to request a Type B meeting to discuss moving directly to a Phase III trial.
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
ALZN closed at $1.18 before the filing and $1.13 on Nov 17, 2026 (-4.24%).
Get alerts when ALZN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days